When 'retatrutide' isn't: what independent testing has found
Last updated: October 3, 2026 · 9 min read · By the Grey Peptides Editorial Board
- No medicine containing retatrutide is approved anywhere. Every vial sold as retatrutide outside a Lilly trial is, at best, unapproved and, at worst, not what the label says.
- Buyer-submitted lab reports show both failures and high-purity passes, but buyers choose which vials to test and which results to publish.
- In Victoria, Australia, seven people were hospitalised with acute liver injury after products labelled retatrutide; the cause has not been established.
- A purity test confirms what peptide is in a sample and how much. It does not check sterility, endotoxins or other contaminants, or whether the next vial matches.
First, what retatrutide legally is
Retatrutide is Eli Lilly's investigational triple agonist of the GLP-1, GIP and glucagon receptors, still in phase 3 trials. In an August 12, 2026 press release announcing six lawsuits against sellers, Lilly stated that no medicine containing retatrutide has been approved for human use by any regulator in the world 1. FDA's page on unapproved GLP-1 drugs, updated June 15, 2026, says retatrutide and cagrilintide cannot be used in compounding under federal law, and that FDA has warned companies selling semaglutide, tirzepatide or retatrutide falsely labelled 'for research purposes' or 'not for human consumption' that were sold directly to consumers with dosing instructions 2.
That is the frame for everything below: a product sold as retatrutide is not a licensed medicine with a manufacturer accountable for its contents. Our retatrutide hub covers the trials; this article covers what has turned up in the vials.
What buyer-submitted lab reports show
Retatrutide has become one of the most-tested gray-market peptides. Buyers send vials to independent analytical laboratories, which return a certificate showing the peptide's identity, often by mass spectrometry, and its purity and quantity by HPLC. Several websites collect these reports. On October 3, 2026, the largest aggregator we checked listed 4,367 retatrutide tests from 378 sellers since December 2024; in its 200 most recent visible tests it recorded 131 passes, 63 failures and 6 incomplete results, and its records include at least one vial that contained none of the labelled peptide 3. A second aggregator reported an average HPLC purity of 99.68% across 1,312 tests 4.
Those two pictures, frequent failures and very high average purity, can both be true, and the reason is how the samples are chosen. Buyers decide which vials to send and which results to share. A seller can submit its own best batch; a buyer who suspects a problem is more likely to test. The laboratory verifies what is in the sample it receives, never where that sample came from, so the seller's name on a report is whatever the submitter declared. Our own lab-results database requires two independent sources before naming any party for exactly this reason 5. Aggregate pass rates from such reports are not a measure of the market; they are a measure of what people chose to test.
| Source of evidence | Who chose the sample | What it shows |
|---|---|---|
| Buyer-submitted lab reports, collected by testing aggregators | Buyers, who decide what to send and whether to publish | Thousands of reports; a sizeable share of failures in one aggregator's visible history (63 fails in 200), very high average purity in another's |
| Regulators and clinicians (Victoria, Australia) | Patients who became ill | Seven hospitalisations for acute liver injury after products labelled retatrutide; cause not yet established |
| Manufacturer (Lilly) | Lilly's own investigations | Six lawsuits; no retatrutide medicine approved anywhere |
| Peer-reviewed test purchases (semaglutide, 2024) | Researchers, buying as consumers | All vials probably substandard or falsified: content 29-39% above label, endotoxin in every sample |
Liver injury in Victoria, Australia
The clearest signal of harm comes from Australia. On June 19, 2026, Victoria's Chief Health Officer issued a health alert: since January 2026 there had been six cases of acute liver injury in people who had used an unapproved peptide product labelled as Retatrutide, sold under names including Reta, R-10 and R-20. The alert asked anyone who had used it and developed unexpected symptoms to seek care, and asked clinicians to consider liver function tests and to ask patients about peptide use 6.
By August 24, ABC News reported a seventh hospitalisation and that a liver transplant specialist had commissioned testing of the products patients used; doctors raised the possibility of a contaminated batch, and Australia's medicines regulator said the concentration of cases in Victoria might point to a particular batch. No laboratory result explaining the injuries had been published 7. Lilly's published trial results, summarised on our hub, report mainly gastrointestinal side effects and a skin-sensation signal 8; whether these products contained retatrutide, something else, or a contaminant is the open question.
If you have used a product labelled retatrutide
Victoria's health department told people who had used these products and developed unusual or unexpected symptoms to seek medical care promptly, and suggested that anyone continuing to use them arrange a review with their doctor to consider liver function tests 6. The department's public warning named abdominal pain, dark urine and yellowing of the skin or eyes as reasons to seek urgent attention 6. Those are signs of liver injury whatever the cause.
If you see a clinician, bring the vial or its packaging, and say what it was sold as, where it came from and when you used it. Doctors in Victoria were specifically asked to question patients about peptide use 6; volunteering it saves time and may help identify a contaminated batch. In the US, problems with unapproved GLP-1 products can be reported to FDA; its unapproved-GLP-1 page has a section on reporting issues and lists the agency's drug information line 2. Reports are how regulators spot a bad batch early, and they matter more for unapproved products, where no manufacturer is collecting safety data.
What testing would actually settle the question
Better evidence is possible. The most useful would be test purchases by researchers or regulators, buying as ordinary customers across many sellers, and testing for identity, quantity, sterility and endotoxin, as the 2024 semaglutide study did on a small scale 9. Results of the testing commissioned in Victoria, once published, could show whether the liver injuries trace to retatrutide, a substitute or a contaminant 7. Until such evidence exists, buyer-submitted certificates remain the main data, with all the selection problems described above.
What researcher-bought samples found for a related drug
The most rigorous kind of testing is a test purchase: researchers buy as ordinary consumers, so the sample is not chosen by the seller. No such peer-reviewed study of retatrutide has been published in PubMed as of October 3, 2026. The closest is a 2024 study of semaglutide sold without prescription online. Of six attempted purchases, three injection vials arrived and three branded pens never did, lost to delivery scams. All three vials were judged probably substandard or falsified: they failed more than half of the visual inspection criteria, contained 29% to 39% more semaglutide than labelled, and every one contained endotoxin, a bacterial toxin that can cause fever and inflammation if injected (test-purchase study) 9.
That study illustrates what buyer-submitted purity reports usually miss: the peptide was the right one and free of peptide-like impurities, yet the products were overdosed and contaminated with endotoxin.
What a passing test does and does not tell you
A typical certificate of analysis for a gray-market peptide answers two questions: is the right molecule present, and how pure and how much is it? A passing result is genuinely useful: it rules out an empty or wrong vial for that sample. It does not show sterility, endotoxin levels, heavy metals or solvent residues unless those were specifically tested, and they usually are not. It applies to one vial from one batch, not the next order. And it cannot tell you whether the dosing a seller suggests is safe, because nobody has established that outside Lilly's trials.
Our guide to spotting a fake COA covers forged certificates, and our COA Decoder explains what each line on a real one means. Even a genuine, passing certificate is a statement about a sample, not a guarantee about a product.
The names are part of the problem
Products sold as retatrutide often avoid the name. Victoria's alert listed 'Reta', 'R-10' and 'R-20' 6, and sellers also use labels such as 'GLP-3', which is not the name of any approved or investigational drug. Our guide to GLP-3 and other gray-market names decodes them. A label that avoids the drug's name is a warning in itself, because it makes the product harder for regulators, platforms and buyers to identify.
Enforcement so far
FDA's actions to date, as listed on its unapproved-GLP-1 page, include warnings to telehealth companies marketing retatrutide, to distributors selling it and to outsourcing facilities repackaging it 2. Lilly's August 2026 lawsuits targeted online sellers claiming 'research use only', a medical spa and a compounding pharmacy, and the company called on platforms, payment processors and shipping companies to stop facilitating sales 1. Enforcement has focused on sellers, not buyers. Our report on gray-market payments and testing spend looks at how the market has responded.
Questions to ask before trusting a retatrutide vial
- Is this a Lilly clinical trial? (As of October 3, 2026, that is the only lawful way to receive retatrutide.)
- Who chose the sample on the certificate, and is it for this exact batch?
- Does the certificate test identity, quantity, sterility and endotoxin, or only identity and purity?
- Is the product sold under the drug's name, or under a code like 'Reta', 'R-10' or 'GLP-3'?
- Would an approved GLP-1 or GIP/GLP-1 drug, prescribed and monitored, meet the same goal? Our Approved-Alternative Finder lists them.
The bottom line
Testing has made the retatrutide gray market look more scientific than it is. Thousands of lab reports exist, including outright failures, but they are chosen by buyers and sellers, verify only the sample sent, and rarely check sterility or contaminants. In Australia, products labelled retatrutide have been linked to seven hospitalisations for liver injury, cause unknown. No retatrutide medicine is approved anywhere. A passing certificate on one vial is not evidence that the next one is safe.
Frequently asked questions
Is retatrutide sold online real?
Some vials contain retatrutide and some do not; buyer-submitted lab reports include both high-purity passes and failures, including vials with none of the labelled peptide. No retatrutide medicine is approved anywhere.
Can a lab test prove retatrutide is safe?
No. A typical certificate confirms identity and purity of one sample. It usually does not test sterility, endotoxin or contaminants, and it says nothing about the next batch.
Has fake retatrutide hurt anyone?
Victoria's health department reported six cases of acute liver injury linked to products labelled retatrutide by June 2026, and a seventh hospitalisation was reported in August. The cause has not been established.
Is retatrutide legal to buy?
It is not approved anywhere. FDA says it cannot be compounded and has warned sellers of 'research use only' versions sold for human use. Lilly says it is available only in its clinical trials.
What names is fake retatrutide sold under?
Victoria's alert listed 'Reta', 'R-10' and 'R-20'. Sellers also use labels such as 'GLP-3', which is not the name of any approved or investigational drug.
Related on Grey Peptides
Sources
- Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (press release announcing six lawsuits). August 12, 2026; read October 3, 2026.
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (sections on retatrutide and cagrilintide, and on products sold 'for research purposes'). Updated June 15, 2026; read October 3, 2026. FDA
- Largest public aggregator of buyer-submitted retatrutide lab reports checked (not linked or named because it ranks sellers): retatrutide page showing 4,367 tests across 378 vendors, December 17, 2024 to September 25, 2026, and 131 pass, 63 fail, 6 incomplete among the 200 most recent visible tests. Read October 3, 2026.
- Second public aggregator of retatrutide HPLC reports (not linked or named because it ranks sellers): 1,312 tests at 99.68% average purity as displayed. Read October 3, 2026.
- Grey Peptides lab-results database, naming rule settled October 1, 2026: one source suffices only if it obtained the sample itself; two independent sources are required for buyer-submitted reports.
- Victorian Department of Health. Health alert: Toxicity linked to unapproved peptide product labelled Retatrutide. Issued June 19, 2026 by the Chief Health Officer; read October 3, 2026.
- ABC News (Australia). Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage. August 24, 2026; read October 3, 2026.
- Grey Peptides encyclopedia entry and hub for retatrutide: trial safety summary (gastrointestinal effects and dysesthesia signal). Read October 3, 2026.
- Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead